Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune reset" Lakefront to host investor conference call on Monday, December 14 at 8 AM ET Mechelen, Belgium; November 4, 2026, 15.01 CET – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the acceptance of a poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting taking place on December 12-15 in New Orleans, LA. "Prior to acquiring Ouro together with Gilead, we recognized gamgertamig’s potential to change clinical practice for pat